The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 918
Piperazine-derived ionizable lipids for enhanced mRNA delivery and cancer immunotherapy
Xu, K. J., Xu, Y., Sun, J., Cheng, X., Lu, C., Chen, W., He, B., & Jiang, T. (2024) · Nano Research · doi:10.1007/s12274-024-6575-8 · Cited by 11
Ototake, M., Inagaki, M., Kimura, S., Onda, K., Tada, M., Kawaguchi, D., Murase, H., Fukuchi, K., Gao, Y., Kokubo, K., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae847 · Cited by 12
Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy
Alshehry, Y., Liu, X., Li, W., Wang, Q., Cole, J., & Zhu, G. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01051-8 · Cited by 13
Mata, E., Broset, E., Matute, C., Stoian, A. M., Adame, S., Alejo, T., López, A., Andrés, B., Heredero, J., de Miguel, D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01201-1 · Cited by 11
Zhang, M., Van, L. M., & Amiji, M. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102686 · Cited by 11
Lau, Y. M. A., Pang, J., Tilstra, G., Couture‐Senécal, J., & Khan, O. F. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2144827 · Cited by 11
Bae, K. H., Shunmuganathan, B. D. O., Zhang, L., Lim, A., Gupta, R., Wang, Y.-M., Chua, B. L., Wang, Y., Gu, Y., Qian, X., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00835-x · Cited by 11
Marcos-Villar, L., Perdiguero, B., Anthiya, S., Borrajo, M. L., Lou, G., Franceschini, L., Esteban, I., Sánchez‐Cordón, P. J., Zamora, C., Sorzano, C. Ó. S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00838-8 · Cited by 11
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman PrimatesPreprint
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M. J., Foulds, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445189 · Cited by 11
Salvatore, V. D., Cernuto, F., Russo, G. L., & Pappalardo, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1628583 · Cited by 10
Inflammatory mediators of mRNA vaccine-induced adverse reactions in mice
Honda, K., Karaki, T., Kunishima, Y., Kawaguchi, Y., Takemura, N., Matsuzaki, T., Fukada, S., Saitoh, T., Hirai, T., & Yoshioka, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.022 · Cited by 10
Prediction of the Apparent pKa Value of Lipid Nanoparticles by Density Functional Theory
Fell, V. H. K., Kramer, T., Heindl, A. H., & Merkel, O. M. (2025) · ACS Materials Au · doi:10.1021/acsmaterialsau.4c00158 · Cited by 10
New ionizable lipids for non-viral mRNA delivery with secondary amine cyclic ether head groups
Dane, E. L., Pote, A. R., Hemmerling, M., Czechtizky, W., Zhou, L., & Bak, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00115c · Cited by 10
Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2
Felgner, J. H., Hernandez‐Davies, J. E., Strahsburger, E., Silzel, E. K., Nakajima, R., Jain, A., Laster, J., Chiang, J.-L., Tsai, Y.-L., Felgner, P. L., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01153-6 · Cited by 10
Shaw, C. A., Stewart-Jones, G. B. E., Jorquera, P. A., Narayanan, E., Elbashir, S. M., Kapłonek, P., Ma, L., Hunter, N., Hanahoe, E., Ketova, T., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127589 · Cited by 11
Self-citationChallenges in Measuring In Vitro Activity of LNP-mRNA Therapeutics
Guerrini, G., Scaccabarozzi, D., Méhn, D., Sarracino, A., Gioria, S., & Calzolai, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178152 · Cited by 11
Sisk, C. K., Turner, L. M., Meraj, S., & Yusuf, N. (2026) · Cells · doi:10.3390/cells15020099 · Cited by 11
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115019 · Cited by 10
New insights on possible vaccine development against SARS-CoV-2
Chaudhry, S. N., Hazafa, A., Mumtaz, M., Kalsoom, U., Abbas, S., Kainaat, A., Bilal, S., Zafar, N., Siddique, A., & Zafar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118421 · Cited by 10
Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11
Shen, K., Yang, C., Chen, C., Ho, H., Chiu, F., Huang, C., Liao, H., Hsu, C., Yu, G., Liao, C., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28370 · Cited by 10
de Chateauneuf-Randon, S., Bresson, B., Ripoll, M., Huille, S., Barthel, É., & Monteux, C. (2024) · Nanoscale · doi:10.1039/d3nr06543j · Cited by 10
Sioud, M., Juzeniene, A., & Sæbøe‐Larssen, S. (2024) · Vaccines · doi:10.3390/vaccines12060624 · Cited by 10
Implicit Solvent with Explicit Ions Generalized Born Model in Molecular Dynamics: Application to DNA
Kolesnikov, E. S., Xiong, Y., & Onufriev, A. V. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c00833 · Cited by 10
Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development
Okuyama, R. (2022) · Pathogens · doi:10.3390/pathogens11121469 · Cited by 11
Alishetty, S., Carrasco, M. J., Alameh, M., Paige, M. A., Said, H., Wright, L., Narayanan, A., Alem, F., Hernandez, K. R., Gillevet, P. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-798453/v1 · Cited by 10
A Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery
Song, S., Baek, J., & Seo, S. (2025) · Scientific Data · doi:10.1038/s41597-025-06456-w · Cited by 13
Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Lu, J., Wei, W., & He, W. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101700 · Cited by 9
Lipid Nanoparticles-Mediated mRNA Delivery to the Eye Affected by Ionizable Cationic Lipid
Dong, S., Pan, Z., Chang, M., Zhou, J., Zhang, M., Chen, Y., Li, T., Chen, Z., Gao, Y., Xie, S., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00248 · Cited by 9
Rostami, N., Alidadi, M., Barzegar, H., Namazifar, F., Noei, H., Hosseini, S., Uversky, V. N., & Ghantabpour, T. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2587715 · Cited by 9
mRNA-lipid nanoparticle vaccines provide protection against lethal Nipah virus infection
Sun, T., Yao, Y., Tian, C., Peng, Y., Liu, Y., Gao, G., Li, Z., Liu, H., Han, J., Chen, M., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01336-1 · Cited by 9
Adjuvant-free cellulose nanofiber vaccine induces permanent humoral immune response in mouse
Ma, R., Xia, W., Zhang, R., Fan, G., Sun, L., Qiu, L., Cui, J., Ju, S., Wu, P., Yang, J., et al. (2022) · Nanotechnology · doi:10.1088/1361-6528/ac705b · Cited by 9
Ke, H., Guay, K. P., Flotte, T. R., Gierasch, L. M., Gershenson, A., & Hebert, D. N. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206103119 · Cited by 9
Delivery of gene editing therapeutics
Kevadiya, B. D., Islam, F. S., Deol, P., Zaman, L. A., Mosselhy, D. A., Ashaduzzaman, M., Bajwa, N., Routhu, N. K., Singh, P. A., Dawre, S., et al. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102711 · Cited by 9
Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs
Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3733 · Cited by 9
Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?
Gupta, R., Arora, K., Arora, N. M., & Kundu, P. K. (2024) · RNA Biology · doi:10.1080/15476286.2024.2399307 · Cited by 11
mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
Waickman, A. T., Victor, K., Newell, K. L., Li, T., Friberg, H., Foulds, K. E., Roederer, M., Bolton, D. L., Currier, J. R., & Seder, R. A. (2022) · JCI Insight · doi:10.1172/jci.insight.160039 · Cited by 11
Hepatotoxicity of nanomaterials: From mechanism to therapeutic strategy
Gao, C., Wang, M., Zheng, Y., Zhang, L., He, J., Liu, B., Lin, X., Mao, J., & Wang, Z. (2024) · Nanotechnology Reviews · doi:10.1515/ntrev-2024-0074 · Cited by 8
The Future of mRNA Vaccines: Potential Beyond COVID-19
Saxena, S., Mandrah, V., Tariq, W., Das, P., Sambhav, K., & Devi, S. H. (2025) · Cureus · doi:10.7759/cureus.84529 · Cited by 8
Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines
Sanyal, G. (2025) · npj Vaccines · doi:10.1038/s41541-025-01181-2 · Cited by 8
WNT7A mRNA Lipid Nanoparticles Promote Muscle Hypertrophy and Reduce Fatty Infiltration
Santiago, L., Oguntuyo, K., Chin-Young, B., Laudier, D. M., Yu, Z., da Silva, P. H. A., Fang, F., Amabile, A., & Han, W. M. (2025) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-025-00859-w · Cited by 8
Clinical insights into extracellular vesicles for targeted myocardial drug delivery
Wang, H., Wei, G., Yin, J., Yang, M., Tong, L., & Wang, J. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2555488 · Cited by 8
Advancing Gene Therapy for Phenylketonuria: From Precision Editing to Clinical Translation
Yu, I., & Jeong, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178722 · Cited by 8
Philipp, J., Sudarsan, A., Kostyurina, E., Meklesh, V., Berglund, M., Rappolt, M., Westergren, J., Lindfors, L., Schwierz, N., & Rädler, J. O. (2025) · Soft Matter · doi:10.1039/d5sm00666j · Cited by 9
Cryer, A. M., Dosta, P., Dion, M. Z., Soto, L. D. L. P., Amar‐Lewis, E., Carmona, G. G. D. L., Perez, A. A. E., Aguilar, D. F. R., Sanchez-Huerta, T. M., Ruiz, B. N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409556122 · Cited by 8
Kunc, M., Whitehead, B. J., Østergaard, L. J., Tolstrup, M., Benn, C. S., Wejse, C. M., & Nejsum, P. L. (2025) · Journal of Clinical Immunology · doi:10.1007/s10875-025-01977-w · Cited by 9
Silica nanoparticles as advanced platforms for nucleic acid delivery
Fanárraga, M. L., & García‐Hevia, L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102921 · Cited by 8
Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era
Borbone, N., Piccialli, I., Falanga, A. P., Piccialli, V., Roviello, G. N., & Oliviero, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084359 · Cited by 9
Zhang, Y., Wang, J., Xing, H., Liu, C., Zha, W., Dong, S., Jiang, Y., & Li, X. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00303e · Cited by 8
Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects
Zangi, A. R., Amiri, A., Pazooki, P., Soltanmohammadi, F., Hamishehkar, H., & Javadzadeh, Y. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05459-0 · Cited by 8
Encapsulating In Vitro Transcribed circRNA into Lipid Nanoparticles Via Microfluidic Mixing
Juchem, M., Cushman, S., Lu, D., Chatterjee, S., Bär, C., & Thum, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3678-7_14 · Cited by 8
Son, S., Park, M., Kim, J. K., & Lee, K. (2024) · Advanced Science · doi:10.1002/advs.202307541 · Cited by 8
Venit, T., Blavier, J., Maseko, S. B., Shu, S., Espada, L., Breunig, C., Holthoff, H., Desbordes, S. C., Lohse, M. J., Esposito, G., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102304 · Cited by 8
Yoon, J., Fagan, E., Jeong, M., & Park, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c03518 · Cited by 8
Tang, X., Zhang, J., Sun, Y., Xu, Z., Huang, T., Liu, X., Song, Y., Zhang, Y., & Deng, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113647 · Cited by 8
Leav, B. A., Straus, W. L., White, P., Leav, A., Gaines, T., Maggiacomo, G., Kim, D., Smith, E. R., Gurwith, M., & Chen, R. T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.005 · Cited by 9
Hashimoto, M., Aoe, S., Kawazu, Y., Seki, N. M., Hashimoto, K., Yoshihara, K., Homma, T., Sonoyama, T., & Omoto, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.092 · Cited by 8
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
Betker, J. L., & Anchordoquy, T. J. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.12.017 · Cited by 8
SARS-CoV-2 and the Vaccination Hype
Sangaletti, P., Doe, J., Gatti, A. M., Arvay, C. G., Giuliani, L., & Lettner, H. (2022) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v2i1.34 · Cited by 8
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530188 · Cited by 8
Harnessing Computational Strategies to Overcome Challenges in mRNA Vaccines
Zhao, S., Chen, J., Dai, T., Li, G., Huang, L., Xin, J., Zhang, Y., Chen, Y., He, X., Huang, H., et al. (2025) · Physiology · doi:10.1152/physiol.00047.2024 · Cited by 7
Kawaguchi, K., Nguyen, L. B. T., Kinoshita, M., Abe, N., Oba, M., Abe, H., Sudo, K., Inoue, K., Uchida, S., & Sawa, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113860 · Cited by 7
Toyonaga, H., Arai, K., Zhang, M., Cheng, L., & Tanaka, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102592 · Cited by 7
Recent Developments of RNA Vaccines and Therapeutics: Reagents, Formulations, and Characterization
Tomeh, M. A., Smith, R. K., & Watkinson, A. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00670 · Cited by 8
Lipid Nanoparticles for the Delivery of mRNA
Paroor, S., Shaji, A. T., Bino, L., Praveen, N., Unnipurath, S., Anil, P., Geo, R., Nagamalleswari, E., Bonam, S. R., & Kurapati, R. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_16 · Cited by 7
Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles
Baghel, S. S., Lokras, A. G., Dias, B. A., Landry, M. R., Cérda, S. L., Wadhwa, A., Herrera‐Barrera, M., Thakur, A., Rades, T., Franzyk, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114385 · Cited by 7
Routes of Nano-drug Administration and Nano-based Drug Delivery System and Toxicity
Gopu, B., Pandian, R., Sevvel, A., & Shukla, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-7834-0_25 · Cited by 7
Current status of vaccine immunotherapy for gastrointestinal cancers
Suzuki, N., Shindo, Y., Nakajima, M., Tsunedomi, R., & Nagano, H. (2023) · Surgery Today · doi:10.1007/s00595-023-02773-y · Cited by 7
Greig, J. A., Jennis, M., Dandekar, A. P., Chorazeczewski, J. K., Param, N. J., So, M., Nayal, M., Bell, P. L., Coughlan, K. A., Choi, M., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.047 · Cited by 7
Ying, B., Liang, C.-Y., Desai, P., Scheaffer, S. M., Elbashir, S. M., Edwards, D. K., Thackray, L. B., & Diamond, M. (2024) · Journal of Virology · doi:10.1128/jvi.00574-24 · Cited by 8
A comprehensive review on lipid-based nanoparticles via nose to brain targeting as a novel approach
Hameed, H., Faheem, S., Younas, K., Jamshaid, M., Ereej, N., Hameed, A., Munir, R., & Khokhar, R. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2404414 · Cited by 7
Mind the Age Gap: Expanding the Age Window for mRNA Vaccine Testing in Mice
Hussain, M., Ferguson-Ugorenko, A., Macfarlane, R., Orr, N., Clarke, S. J., Wilkinson, M. J. A., Horan, L., & Perrie, Y. (2025) · Vaccines · doi:10.3390/vaccines13040370 · Cited by 7
Respiratory mucosal vaccines: Applications, delivery strategies and design considerations
Shi, T., Ye, Y., Fan, Z., Yang, Q., Ma, Y., & Zhu, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118326 · Cited by 8
Kimura, S., & Harashima, H. (2024) · BioDrugs · doi:10.1007/s40259-024-00647-4 · Cited by 8
Suzuki-Okutani, M., Okamura, S., Gis, T., Sasaki, H., Lee, S. P., Kashiwabara, A., Goto, S., Matsumoto, M., Yamawaki, M., Miyazaki, T., et al. (2024) · eLife · doi:10.7554/elife.97532.3 · Cited by 7
Canali, S., Fischer, A. W., Nguyen, M., Anderson, K. E., Wu, L., Graham, A.-R., Hsiao, C. J., Bankar, C., Dussault, N., Ritchie, V., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101965 · Cited by 6
Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines
Chentoufi, A. A., Ulmer, J. B., & BenMohamed, L. (2024) · Vaccines · doi:10.3390/vaccines13010030 · Cited by 7
Cholesterol Within Phosphatidylcholine Liposomes Attenuates the Expression of Cytokines
Cauvi, D. M., Hawisher, D., Derunes, J., Aniegbuna, I., & Maio, A. D. (2025) · The FASEB Journal · doi:10.1096/fj.202501458r · Cited by 6
Exploring the future of mRNA delivery: Beyond lipid nanoparticles
Gabelmann, A., Biesel, A., Loretz, B., & Lehr, C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152347 · Cited by 6
Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons
Dong, L., Wang, J., & Xia, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-62981-7 · Cited by 6
Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells
Trines, M. M., Hoorn, D., Hofstraat, S. R. J., Zwolsman, R. C., Anbergen, T., Versteeg, I., van Elsas, Y., Deckers, J., Hendrikx, M., Kleuskens, T., et al. (2025) · Advanced Materials · doi:10.1002/adma.202504830 · Cited by 8
Han, Y., Zhang, K., Xin, N., Gao, X., Ma, G., An, J., & Li, Y. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139025 · Cited by 6
Optimizing the targeting of lipid nanoparticles for gene therapy
Yue, L., Gao, X., Qi, W., Zhang, L., & Wang, Y. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00351b · Cited by 6
Canestrale, A. R., Kholia, S., Dimuccio, V., & Sanchez, M. B. H. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm16010001 · Cited by 6
mRNA technology for the prevention and treatment of HIV-1 infection
Chuang, L. I. U., Yaremenko, A. V., Li, X., You, X., Zhu, X., Liu, N., Chen, W., Kong, N., Xie, T., Gaiha, G. D., et al. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00387-2 · Cited by 6
From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function
Quagliarini, E., Pozzi, D., & Caracciolo, G. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505261 · Cited by 6
Han, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 8
Yamagata, H. M., Padilla, M. S., Hamilton, A. G., Swingle, K. L., Thatte, A. S., Ricciardi, A. S., Agrawal, A., Fitzgerald, E., Poirier, A. J., Geisler, H. C., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c00080 · Cited by 6
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
Immunological mechanisms of mRNA vaccines for infectious diseases
Locci, M., & Pardi, N. (2026) · Nature · doi:10.1038/s41586-026-10599-0 · Cited by 6
Nanotechnology in COVID-19 Vaccines
Jain, A., & Sharma, S. (2022) · doi:10.2991/978-94-6463-020-6_3 · Cited by 6
Ionizable Lipids with Triazole Moiety from Click Reaction for LNP-Based mRNA Delivery
Wang, Y., Si, X., Feng, Y., Feng, D., Xu, X., & Zhang, Y. (2023) · Molecules · doi:10.3390/molecules28104046 · Cited by 6
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Robinson, S. R., Dayao, D., Medina, J. A., Martone, C. J., Yauch, A. K., Hinkley, T. C., Erasmus, J. H., Shoemaker, C. B., & Tzipori, S. R. (2024) · Infection and Immunity · doi:10.1128/iai.00239-24 · Cited by 6
Machado, K. L. L. L., Burian, A. P. N., Martins‐Filho, O. A., Mill, J. G., Ferreira, L. B., Tapia, K. R. L., Moulin, A. C. S., Moulaz, I. R., Ribeiro, P. D. C., Magalhães, V. D. O., et al. (2024) · Vaccines · doi:10.3390/vaccines12121367 · Cited by 6
RNA-lipid nanoparticle therapeutics for women’s health
Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 7
Abisoye-Ogunniyan, A., Carrano, I. M., Weilhammer, D. R., Gilmore, S. F., Fischer, N. O., Pal, S., de la Maza, L. M., Coleman, M. A., & Rasley, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768461 · Cited by 6
Hausig, F., Dekevic, G., Sobotta, F. H., Solomun, J. I., Richter, F., Salzig, D., Traeger, A., & Brendel, J. C. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202200517 · Cited by 6
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
